Form 4: Vigil Neuroscience Executive Receives Repriced Stock Option Award

David L.F. Gray, Chief Science Officer of Vigil Neuroscience, Inc., had his stock option award repriced to $3.03 per share on May 3, 2024, under the company's 2021 Stock Option and Incentive Plan.

Summary

• On May 3, 2024, Vigil Neuroscience's Board of Directors approved a repricing of a stock option award for David L.F. Gray, the Chief Science Officer.
• The exercise price was adjusted to $3.03 per share, reflecting the fair market value of the company's common stock on that date.
• The repriced stock option award will revert to its original exercise price of $12.09 if exercised during the one-year Retention Period, or upon a Sale Event, termination of employment by the company without cause, or termination of employment for Good Reason.
• Gray now holds 267,000 stock options at the new exercise price of $3.03, in addition to the existing 267,000 options at the original price of $12.09.
• The options vest over time, with 25% vested on February 27, 2024, and the remainder vesting monthly until February 27, 2033.

Sentiment

Score: 6

Explanation: The document itself is neutral, detailing a standard compensation adjustment. The sentiment is slightly positive as it suggests efforts to retain key personnel, but the potential reversion clause introduces some uncertainty.

Positives

• The repricing of the stock options may incentivize the Chief Science Officer to remain with the company and contribute to its success.
• Aligning the exercise price with the current market value could make the options more attractive to the executive.
• The Retention Period provides a mechanism to ensure the executive's continued commitment to the company.

Negatives

• The repricing of stock options could be viewed negatively by shareholders if it is perceived as rewarding underperformance.
• The potential reversion to the original exercise price under certain conditions adds complexity to the option structure.

Risks

• The 'Retention Period' introduces uncertainty, as the exercise price could revert to the original price under specific circumstances.
• The value of the stock options is dependent on the future performance of Vigil Neuroscience's stock.

Future Outlook

The document does not contain explicit forward-looking statements, but the repricing of stock options suggests an ongoing effort to incentivize key personnel.

Management Comments

• The Issuer's Board of Directors approved a stock option award repricing, effective as of May 3, 2024.

Industry Context

Stock option repricing is a common practice in the biotechnology industry to retain and incentivize key employees, especially when a company's stock price has declined. This ensures that the options remain a valuable incentive for the employee.

Comparison to Industry Standards

• Stock option repricing is a common practice in the biotech industry, particularly for companies with volatile stock prices.
• Companies like BioMarin Pharmaceutical and Amgen have used similar strategies to retain key employees during periods of stock price decline.
• The vesting schedule and retention period are fairly standard compared to industry norms for executive compensation packages.

Stakeholder Impact

• Shareholders may view the repricing as a positive sign of management's commitment to the company, or negatively if they believe it rewards underperformance.
• Employees may see the repricing as a positive sign of the company's commitment to its employees.
• The repricing has no direct impact on customers, suppliers, or creditors.

Key Dates